Human Immunodeficiency Virus Type 1 (HIV-1) Vpr Enhances Expression from Unintegrated HIV-1 DNA
Open accessAbstract
Retroviral DNA synthesized prior to integration, termed unintegrated viral DNA, is classically believed to be transcriptionally inert and to serve only as a precursor to the transcriptionally active integrated proviral DNA form. However, it has recently been found to be expressed under some circumstances during human immunodeficiency virus type 1 (HIV-1) replication and may play a significant role in HIV-1 pathogenesis. HIV-1 Vpr is a virion-associated accessory protein that is critical for HIV-1 replication in nondividing cells and induces cell cycle arrest and apoptosis. We find that Vpr, either expressed de novo or released from virions following viral entry, is essential for unintegrated viral DNA expression. HIV-1 mutants defective for integration in either the integrase catalytic domain or the cis -acting att sites can express unintegrated viral DNA at levels similar to that of wild-type HIV-1, but only in the presence of Vpr. In the absence of Vpr, the expression of unintegrated viral DNA decreases 10- to 20-fold. Vpr does not affect the efficiency of integration from integrase-defective HIV-1. Vpr-mediated enhancement of expression from integrase-defective HIV-1 requires that the viral DNA be generated in cells through infection and is mediated via a template that declines over time. Vpr activation of expression does not require exclusive nuclear localization of Vpr nor does it correlate with Vpr-mediated cell cycle arrest. These results attribute a new function to HIV-1 Vpr and implicate Vpr as a critical component in expression from unintegrated HIV-1 DNA.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Retaining the Vpr accessory protein via transcriptional activation of the HIV-1 LTR can enhance expression of integrase-defective lentiviral vectors.
“Another approach to enhance the expression of integrase-defective LVs is by retaining the Vpr accessory protein via transcriptional activation of the HIV-1 LTR [74].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [74]
Cites
Eckstein, D. A., Sherman, M. P., Penn, M. L., Chin, P. S., De Noronha, C. M. C., Greene, W. C., & Goldsmith, M. A. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.10.1407 · Cited by 124 · see citing works
Masuda, T., Kuroda, M. J., & Harada, S. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8396-8402.1998 · Cited by 83 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Transient Gene Expression by Nonintegrating Lentiviral Vectors
Nightingale, S. J., Hollis, R. P., Pepper, K. A., Petersen, D., Yu, X.-J., Yang, C., Bahner, I., & Kohn, D. B. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.008 · Cited by 192 · see citing works
Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector
Negri, D. R., Michelini, Z., Baroncelli, S., Spada, M., Vendetti, S., Buffa, V., Bona, R., Leone, P., Klotman, M. E., & Cara, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300241 · Cited by 84 · see citing works
Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through
Gurumoorthy, N., Nordin, F., Tye, G. J., Wan Kamarul Zaman, W. S., & Ng, M. H. (2022) · Biomedicines · doi:10.3390/biomedicines10010107 · Cited by 69 · see citing works
The old and the new: Prospects for non-integrating lentiviral vector technology
Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58 · see citing works
Hakata, Y., Miyazawa, M., & Landau, N. R. (2014) · Virology Journal · doi:10.1186/1743-422x-11-108 · Cited by 13 · see citing works
- Authors
- Poon, B., & Chen, I. S. Y.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2003-04
- Volume
- 77
- Issue
- 7
- Pages
- 3962-3972
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC150668
- OpenAlex
- W2108498026
- Cited by
- 105
- References
- 2
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 6 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 4 · 2015: 1 · 2014: 3 · 2013: 4 · 2012: 5
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (CA70018, R01CA070018)
- National Institute of Allergy and Infectious Diseases (AI-28 697, AI 43190, R01AI043190, P30AI028697)
- Center for AIDS Research, University of California Los Angeles
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1 Vpr, unintegrated viral DNA, HIV-1 transcription, viral integration, integrase, att site, accessory proteins, viral pathogenesis, cell cycle arrest, apoptosis
- MeSH terms
- Cell Line, Defective Viruses, DNA, Viral, HeLa Cells, Humans, Transcription, Genetic, HIV-1, Transcriptional Activation, Up-Regulation, Gene Expression, HIV Long Terminal Repeat, Genes, vpr, Gene Products, vpr, Virus Integration, HIV Integrase, vpr Gene Products, Human Immunodeficiency Virus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review